Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

@article{Wallemacq2009OpportunitiesTO,
  title={Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference},
  author={Pierre E. Wallemacq and Victor William Armstrong and Merc{\`e} Brunet and Vincent Haufroid and David W Holt and Atholl Johnston and Dirk R J Kuypers and Yannick Le Meur and Pierre Marquet and Michael Oellerich and Eric Thervet and Burkhand Toenshoff and Nasrullah Undre and Lutz Thorsten Weber and Ian S. Westley and Michel Mourad},
  journal={Therapeutic Drug Monitoring},
  year={2009},
  volume={31},
  pages={139-152}
}
In 2007, a consortium of European experts on tacrolimus (TAC) met to discuss the most recent advances in the drug/dose optimization of TAC taking into account specific clinical situations and the analytical methods currently available and drew some recommendations and guidelines to help clinicians with the practical use of the drug. Pharmacokinetic, pharmacodynamic, and more recently pharmacogenetic approaches aid physicians to individualize long-term therapies as TAC demonstrates a high degree… Expand
Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.
TLDR
The current challenges and opportunities for the translation of pharmacogenetic information of tacrolimus into clinical settings are discussed and it is feasible to span all clinically actionable genotypes and provide patients with relevant information throughout their lifetime. Expand
Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients
TLDR
Traditional TDM, perhaps following pre-emptive genotyping for Tac-metabolizing enzymes, must suffice for a few years before these strategies can be implemented in clinical practice. Expand
Study of the Influence of a Combination of Pharmacogenetic Variables on Tacrolimus Exposure: A Population Pharmacokinetic Approach
TLDR
A population-based Bayesian prediction tool for initial dose calculation and dose adaptation during the post-transplant period through characterizing the Tacrolimus population PK using an intensive sampling and confirming the best limiting sampling strategy to be applied during dose adaptation. Expand
PREDICTIVE PERFORMANCES OF DIFFERENT THERAPEUTIC DRUG MONITORING APPROACHES TO ASSESS TACROLIMUS AND MYCOPHENOLIC ACID EXPOSURE
TLDR
Comparing performances of three different approaches of C0 based TDM of these two drugs, in their ability to predict MPA and TAC area under the curve (AUC), found the Bayesian estimators performed much better than the two other approaches, followed by linear regression models. Expand
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
TLDR
It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients. Expand
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
TLDR
Pharmacogenetic adaptation of the daily dose of tacrolimus is associated with improved achievement of the target C0, and whether this improvement will affect clinical outcomes requires further evaluation. Expand
Therapeutic Drug Monitoring of Everolimus: A Consensus Report
TLDR
EVR trough concentrations (C0) demonstrate a good relationship with overall exposure, providing a simple and reliable index for TDM, and a fully validated liquid chromatography tandem mass spectrometry assay is the preferred method for determination of EVR C0. Expand
Therapeutic monitoring of pediatric transplant patients with conversion to generic tacrolimus.
TLDR
No significant differences in terms of laboratory parameters, drug exposure and dose were observed in the study population, and the need of close monitoring to ensure a safe interchange, especially in vulnerable populations such as the pediatric is emphasized. Expand
Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management.
TLDR
A high IPV in Tac exposure has recently been recognized as a strong risk factor for acute rejection and poor long-term kidney transplantation outcome. Expand
Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients
TLDR
It has been suggested that once-daily administration of tacrolimus may improve patient compliance, but further studies are required to demonstrate this and whether formulation conversion is worthwhile in the longer term. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 149 REFERENCES
Therapeutic monitoring of sirolimus: its contribution to optimal prescription.
TLDR
It is concluded that the development of sirolimus has benefited from experience gained during the pharmacokinetic assessment of other immunosuppressive drugs, both when used in combination with cyclosporine and when used after cyclOSporine withdrawal. Expand
Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation
  • Martin N. Lee, L. Butani
  • Medicine
  • Pediatric transplantation
  • 2007
TLDR
Although the overall correlation between T trough and AUC is good, it is suboptimal in the first post‐transplant month in children receiving steroids, and it is recommended AUC monitoring for T. Expand
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
TLDR
Critics have started to question current reliance on trough measurement during therapeutic drug monitoring, with instances of toxicity and rejection occurring when trough concentrations are within ‘acceptable’ ranges, and controversy exists as to whether this will provide any great benefit, given the added complexity in monitoring. Expand
Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients
TLDR
The rate and extent of tacrolimus absorption after oral administration do not seem to be altered in paediatric patients, but oral doses need to be generally 2-fold higher than corresponding adult doses to reach similar tacolimus blood concentrations. Expand
Beyond Cyclosporine: A Systematic Review of Limited Sampling Strategies for Other Immunosuppressants
TLDR
This systematic review paper focuses on other immunosuppressive agents and categorizes the 24 pertinent citations according to the U.S. Preventive Services Task Force rating scale. Expand
AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.
TLDR
This simple, flexible method provides the opportunity to tailor immunosuppression, and should help minimize tacrolimus-related toxicity, such as nephrotoxicity and post-transplant diabetes mellitus. Expand
Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation.
TLDR
The guidelines provided in this article based on the experience of four major US transplant centers, cover issues related to dosing, blood levels, concomitant use of mycophenolate mofetil (MMF), antifungal and antiviral prophylaxis, and drug interactions. Expand
Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients.
TLDR
Some biomarkers that have been proposed to evaluate currently approved immunosuppressants, such as target enzymes, cytokines, lymphocyte activation biomarkers, and cellular immune response, are reviewed, as well as the most promising results in this field. Expand
First Clinical Experience With the New Once-Daily Formulation of Tacrolimus
  • M. First
  • Medicine
  • Therapeutic drug monitoring
  • 2008
TLDR
The tacrolimus once-daily regimen may improve compliance while enabling the use of the same patient care strategies, total daily dose, target trough concentrations, and therapeutic monitoring techniques as currently used with the twice-a-day formulation of tacro Limus. Expand
Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation
  • C. Staatz, C. Willis, P. Taylor, S. Lynch, S. Tett
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
Patient outcomes in transplantation would improve if dosing of immunosuppressive agents was individualized and Pharmacokinetic information obtained will assist in tacrolimus dosing; however, further investigation into reasons for the pharmacokinetic variability of tacolimus is required. Expand
...
1
2
3
4
5
...